Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  MiMedx Group Inc    MDXG

MIMEDX GROUP INC (MDXG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Dr. Gloria Matthews Joins MiMedx As Its Senior Vice President Of Research And Development

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 10:30am CEST

Release date- 04102017 - MARIETTA, Ga. - MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent protected processes for multiple sectors of healthcare, announced today that Dr. Gloria Matthews has joined the Company as its Senior Vice President, Research and Development.

Dr. Matthews will lead the Company's overall research function as well as the development of new products.

Parker H. 'Pete' Petit, Chairman and CEO, stated, 'Dr. Matthews brings over 20 years of experience encompassing programs from discovery into Phase 3 clinical development for devices, orthobiologics, combination products, and new chemical entities for osteoarthritis, cartilage repair, and regenerative medicine. She is an accomplished scientific leader with broad ranging expertise in orthopedic and rheumatologic diseases, among other therapeutic areas, and she has significant functional experience in cellular and gene therapy, biomaterials and growth factors.'

Bill Taylor, President and COO, commented, 'The addition of Dr. Matthews to our staff is an important step in our continued expansion into biopharmaceuticals. We will continue to expand our clinical and scientific talent and resources to further drive our growth in this area. We are very excited to welcome Dr. Matthews to our organization.'

Immediately prior to joining MiMedx, Dr. Matthews served as Chief Medical Officer at Histogenics Corporation, where she oversaw all clinical and medical affairs activities with strategic oversight of various United States and global development programs across biologics, drugs and devices.

Prior to Histogenics, Dr. Matthews spent 12 years at Genzyme Corporation and Sanofi Genzyme. During her tenure at Genzyme, Dr. Matthews held progressively more responsible leadership positions and was involved in clinical and preclinical development and/or post-market support of cell, gene, growth factor, small molecule and biomaterial based products in the orthopedic and rheumatologic space. Dr. Matthews last served with Sanofi Genzyme in the role of Senior Director and Global Head of Bone and Joint Disease Research and Development.

Dr. Matthews earned her DVM and Ph.D. from Cornell University. Dr. Matthew's Ph.D. concentration was in cell and molecular biology of osteoarthritis.

The Company also reaffirmed its previously communicated revenue expectations for the third quarter of 2017. 'In our press releases of September 5 and September 13, 2017, we communicated that we expected to exceed the $80 million upper end of our forecasted third quarter revenue range in spite of the disruption from Hurricane Harvey and Hurricane Irma. Our preliminary revenue estimates clearly show that our forecasting was correct. We are experiencing robust revenue growth, and we look forward to reporting our actual third quarter revenue on or about the 13th of October,' added Petit.

About MiMedx

MiMedx is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. 'Innovations in Regenerative Medicine' is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Important Cautionary Statement

This press release includes forward-looking statements, including statements regarding revenue expectations for the 2017 third quarter and expectations for sales performance, despite the effects of Hurricane Harvey and Hurricane Irma. These statements also may be identified by words such as 'believe,' 'except,' 'may,' 'plan,' 'potential,' 'will' and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the risk that the Company's revenue for the 2017 third quarter may not materialize as expected and that the Company's sales performance, may be more negatively impacted than anticipated due to Hurricane Harvey and Hurricane Irma. For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward looking statement.

Contact:

Rich Cockrell

Tel: 877-889-1972

Email: investorrelations@thecockrellgroup.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
HISTOGENICS CORP 6.59% 0.597 Delayed Quote.-70.88%
MIMEDX GROUP INC 12.73% 6.2 Delayed Quote.-56.38%
SANOFI -0.60% 74.67 Real-time Quote.3.92%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MIMEDX GROUP INC
04:03aMIMEDX GROUP INC : Kaskela Law LLC Announces Investigation of MiMedx Group, Inc...
AC
09/20MIMEDX GROUP, INC. : Change in Directors or Principal Officers, Regulation FD Di..
AQ
08/31MIMEDX GROUP, INC. : Termination of a Material Definitive Agreement (form 8-K)
AQ
08/27MIMEDX : Announces Statistically Significant Results in New Multicenter Clinical..
AQ
08/22MIMEDX : Georgia State's top donor gifts potentially inflated stock
AQ
08/20MIMEDX : Provides Additional Information and Context to Wall Street Journal Arti..
AQ
08/20MIMEDX : Receives Additional Nasdaq Listing Notice Due to Late Form 10-Q
AQ
08/16MIMEDX : Patent Application Titled "Tissue Grafts Composed Of Micronized Placent..
AQ
08/16MIMEDX : Receives Regulatory Approval to Commercialize Product Portfolio in Aust..
AQ
08/16MIMEDX : Health Insurer Shuns 'Unproven' Amniotic-Tissue Products -- Update
DJ
More news
News from SeekingAlpha
09/20VA boots five docs connected MiMedx; investors unmoved, shares up 12% 
09/20HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (09/20/2018) 
09/10Healthcare And Biotechnology Dashboard - Update 
09/01STOCKS TO WATCH : Time To Talk Valuation 
08/24PREMARKET GAINERS AS OF 9 : 05 am (08/24/2018) 
Financials ($)
Sales 2017 322 M
EBIT 2017 58,9 M
Net income 2017 38,1 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 16,84
P/E ratio 2018 17,19
Capi. / Sales 2017 1,89x
Capi. / Sales 2018 1,58x
Capitalization 611 M
Chart MIMEDX GROUP INC
Duration : Period :
MiMedx Group Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 18,5 $
Spread / Average Target 236%
EPS Revisions
Managers
NameTitle
David Coles Chief Executive Officer
Charles Robert Evans Chairman
Edward J. Borkowski Chief Financial Officer & Executive Vice President
Frank Burrows Vice President-Clinical & Scientific Liaison
Thomas J. Koob Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
MIMEDX GROUP INC-56.38%611
MEDTRONIC PLC19.98%130 270
BAXTER INTERNATIONAL19.49%41 480
ALIGN TECHNOLOGY73.71%30 517
ZIMMER BIOMET HOLDINGS7.60%26 421
HOYA CORPORATION15.10%22 460